Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives

Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in ne...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular intervention and therapeutics 2022-04, Vol.37 (2), p.255-263
Main Authors: Natsuaki, Masahiro, Sonoda, Shinjo, Yoshioka, Goro, Hongo, Hiroshi, Kaneko, Tetsuya, Kashiyama, Kuninobu, Yokoi, Kensuke, Hikichi, Yutaka, Node, Koichi
Format: Article
Language:English
Subjects:
Cardiology
Drug Therapy, Combination
Drug-Eluting Stents - adverse effects
Humans
Interventional Radiology
Invited Review Article
Medicine
Medicine & Public Health
Percutaneous Coronary Intervention - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y 12 inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y 12 inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI.
ISSN:1868-4300
1868-4297
DOI:10.1007/s12928-022-00847-1